45,738 Establishment Labs Holdings Inc. $ESTA Shares Sold by William Blair Investment Management LLC

William Blair Investment Management LLC cut its stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 6.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 668,313 shares of the company’s stock after selling 45,738 shares during the period. William Blair Investment Management LLC’s holdings in Establishment Labs were worth $42,886,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in Establishment Labs in the 2nd quarter worth about $135,752,000. Bank of America Corp DE bought a new stake in shares of Establishment Labs during the second quarter valued at approximately $52,176,000. Rice Hall James & Associates LLC bought a new stake in shares of Establishment Labs during the second quarter valued at approximately $48,134,000. Nantahala Capital Management LLC purchased a new stake in shares of Establishment Labs in the second quarter valued at approximately $28,817,572. Finally, Bamco Inc. NY purchased a new stake in shares of Establishment Labs in the second quarter valued at approximately $24,550,000. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Establishment Labs Stock Up 3.1%

NASDAQ ESTA traded up $2.13 on Friday, hitting $70.75. The stock had a trading volume of 367,353 shares, compared to its average volume of 513,910. The business’s fifty day moving average price is $66.04 and its 200 day moving average price is $72.37. The company has a debt-to-equity ratio of 17.17, a current ratio of 3.57 and a quick ratio of 2.52. Establishment Labs Holdings Inc. has a 52-week low of $53.16 and a 52-week high of $97.59. The stock has a market cap of $2.11 billion, a price-to-earnings ratio of -55.27 and a beta of 1.03.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Friday, October 30th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.09). The business had revenue of $71.99 million during the quarter, compared to analysts’ expectations of $66.81 million. Establishment Labs had a negative net margin of 14.56% and a negative return on equity of 196.38%. The company’s quarterly revenue was up 33.8% compared to the same quarter last year. During the same quarter last year, the business posted ($0.38) earnings per share. Equities research analysts anticipate that Establishment Labs Holdings Inc. will post -1.18 earnings per share for the current year.

Analyst Upgrades and Downgrades

ESTA has been the topic of several research reports. TD Cowen reduced their price objective on Establishment Labs from $117.00 to $95.00 and set a “buy” rating on the stock in a report on Monday, October 26th. Stifel Nicolaus initiated coverage on Establishment Labs in a report on Wednesday, October 14th. They issued a “buy” rating and a $85.00 target price for the company. Canaccord Genuity Group set a $105.00 target price on Establishment Labs in a report on Thursday, August 6th. BTIG Research dropped their price target on Establishment Labs from $103.00 to $93.00 and set a “buy” rating on the stock in a research report on Thursday, October 29th. Finally, JPMorgan Chase & Co. raised their price target on Establishment Labs from $84.00 to $95.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Establishment Labs has an average rating of “Moderate Buy” and a consensus target price of $95.00.

About Establishment Labs

Establishment Labs Holdings Inc. is a medical technology company focused on breast health and aesthetics. Founded in 2004 by Juan José Chacón-Quirós, the Costa Rica-based company develops and manufactures products for breast augmentation and reconstruction. Its product portfolio includes Motiva breast implants, offered in different shapes and designs, as well as related technologies and products for plastic and reconstructive surgery. The company also develops solutions intended to support surgical procedures and patient care.